SBIR/STTR Research Award
Synthetic antibodies for monitoring modified RNAs
Award amount
$225,000Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ROCKLAND IMMUNOCHEMICALS, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- NFKNUGEMMY18
- Solicitation number
- DA15-001
- Topic code
- NIDA
Research abstract
DESCRIPTION (provided by applicant): Post-transcriptional RNA modification plays an important role in biological processes. For example, adenosines to nosiness or A-to-I editing are most abundant in the central nervous system (CNS) and essential for normalCNS development. Presently, the available reagents for detection, quantitation, or immunoprecipitation of modified RNA are extremely limited. Rockland Immunochemicals is collaborating with Aptagen to develop synthetic antibodies for detection and quantitation of modified RNAs. In Phase I, as a proof-of-principle, high-affinity and target-specific aptamers and aptamer-based detection assays for inosine and N6- methyladenosine containing RNA will be developed. In Phase II, aptamer reagents and assays to morethan 60 RNA modifications known in eukrayotes will be developed. These affinity reagents will be used in microarrays to profile RNA modifications in different mouse CNS disorder models. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE:
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- IGF OT IGF SYSTEMIC PRE TARGETED RADIOIMMUNOTHERAPY WITH BISPECIFIC NANOBODIES FOR CANCER TREATMENT
- Developing a Point-of-Care Device for the Diagnosis of Sickle Cell Disease in Low Resource Settings
- TOPIC 324 PHASE I 9 MONTH FUNDING; NOVEL IMAGING AGENTS T EXPAND TE CLINICAL TOOL
- SBIR TOPIC 229, PHASE II: PHARMACODYNAMIC ASSAY FOR AKT FOR USE WITH PI3K/AKT/MTOR INHIBITORS
- TAS::75 0849::TAS SBIR TOPIC 292 PHASE I DEVELOPMENT OF MOLECULAR PHARMACODYNAMIC ASSAYS FOR TARGETED THERAPIES
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Wearable Wireless Respiratory Monitoring System that Detects and Predicts Opioid Induced Respiratory Depression
- Building and testing the Life Enhancement and Advocacy Programming digital training tool (LEAPLink) to better serve people with lived experience of homelessness and substance use disorder
- A digital intervention to decrease self-stigma among pregnant and postpartum women with opioid use disorder
- Development of medication for the treatment of respiratory depression due to opioid (prescribed or illicit) overdose/multidrug (polysubstance) overdose in a hospital or community setting.
- Creation and Validation of the Dose-Opioid-Source Evaluation tool (DOSE) - a Robust Opioid Use Clinical Outcome Assessment for Qualification as an FDA Medical Device Development Tool (MDDT)
Research funding history
11 SBIR/STTR records share this UEI (2008–2016). Reported award amounts total $3,800,913. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services